

Shield Therapeutics plc
("Shield" or the "Company" or the "Group")

Results of 2022 Annual General Meeting

London, UK, 27 July 2022: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company focused on the commercialization of Accrufer®/Feracru® (ferric maltol), a novel, oral iron therapy differentiated from other conventional irons by its efficacy, well-tolerated formulation, and broad indication, announces the results of the voting for each of the resolutions as set out in the Notice of Annual General Meeting 2022. The Board reports that resolutions 1 to 10 passed as ordinary resolutions and resolutions 11 and 12 were passed as special resolutions, full details are shown below.

The following table shows the votes cast on each resolution:

	VOTES FOR	%	VOTES AGAINST	%	WITHHELD VOTES
Resolution 1	78,956,948	98.64%	1,084,971	1.36%	96,410
Resolution 2	78,834,489	98.56%	1,152,138	1.44%	151,702
Resolution 3	78,812,028	98.53%	1,174,599	1.47%	151,702
Resolution 4	78,848,263	98.58%	1,138,364	1.42%	151,702
Resolution 5	79,706,568	99.65%	281,098	0.35%	150,663
Resolution 6	79,694,216	99.63%	292,411	0.37%	151,702
Resolution 7	79,729,610	99.66%	270,986	0.34%	137,733
Resolution 8	79,078,603	98.80%	958,397	1.20%	101,329
Resolution 9	79,939,681	99.83%	138,207	0.17%	60,441
Resolution 10	79,744,797	99.57%	342,264	0.43%	51,268
Resolution 11	79,614,031	99.48%	415,142	0.52%	109,156
Resolution 12	78,757,527	98.41%	1,271,646	1.59%	109,156

Notes:

1. Number of shares in issue 216,192,462.
2. Details of the votes received on the resolutions are available on the Company's website: <https://www.shieldtherapeutics.com/corporate-documents/>.
3. Shield Therapeutics plc LEI: 213800G74QWY15FC3W71.

For further information please contact:

Shield Therapeutics plc

Greg Madison, CEO
Hans-Peter Rudolf, CFO

www.shieldtherapeutics.com

+44 (0) 191 511 8500

Nominated Adviser and Joint Broker

Peel Hunt LLP

James Steel/Christopher Golden

+44 (0)20 7418 8900

Joint Broker

finnCap Ltd

Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks

+44 (0)20 7220 0500

Financial PR & IR Advisor**Walbrook PR**

Lianne Applegarth/Alice Woodings

+44 (0)20 7933 8780 or shield@walbrookpr.com**Investor Contact (US Advisor)**

LifeSci Advisors, LLC

John Mullaly

+1 617 429 3548 or jmullaly@lifesciadvisors.com**About Accrufer®/Feraccru®**

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s

Accrufer®/Feraccru® are registered trademarks of the Shield Group